The authors note that CYP1A1*2A polymorphism correlates with the response to EGFR-TKIs of NSCLC, wild type T/T patients having an improved response of inhibitors versus T/C and C/C alleles. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.